Open

PIK3CA Related Overgrowth Syndromes (PROS) Clinical Trial

This is a study to understand how safe and effective a medication (alpelisib) is in patients with PIK3CA Related Overgrowth Syndromes (PROS). We will be studying adults and children who are at least 6 years of age.

Age & Gender

6 years ~ 99 years
Male, Female, Gender Inclusive

Visit Availability

Standard business hours (M-F, 8-5)
Visits can be combined with regular clinical appointments

Location

Georgia, North Carolina (Statewide), South Carolina, Tennessee, Virginia, West Virginia

What will be asked of you

At each visit you (or your child) will meet with members of the study team. Visits for the first year are monthly then every 6 months for the rest of the study. Visits will take anywhere from 2 hrs to 2 days as an outpatient and may include talking, physical examination, questionnaires, blood draws, studies of heart and lung function (EKGs, echocardiograms, lung function tests), MRI scans and photographs of your (or your child's) body, and other X-rays.

Incentives

Gas and parking assistance, study drug at no cost for the duration of the study, meals for long clinic visits, hotel assistance for 2-day visits.

In-person visits:
27

Total length of participation:
5 years

Looking for Specific Volunteers

Able to participate:

Your (or your child's) doctor has told you that you have PROS
You (or your child) has had this confirmed by genetic testing from a biopsy.

Not eligible if:

You are a pregnant or nursing female
You are a sexually active male and not willing to use contraception
You have had alpelisib before or are on other "targeted" drugs for PROS such as sirolimus
You are not able to keep frequent appointments

Contact the Team

Visit Location

Contact & Visit Location

Primary Contact

Primary Visit Location

Clinical and Translational Research Center (CTRC)
Burnett-Womack Building (UNC-Chapel Hill)
160 Dental Cir, Chapel Hill, NC 27514, USA

Additional Study Information

Principal Investigator

Julie Blatt
Pediatrics - Hematology/Oncology

Study Type

Clinical or Medical
Interventional

Study Topics

Rare Diseases

IRB Number

21-0169

ClinicalTrials.gov

NCT04589650

Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Helpful Links

Questions?

This email address is being protected from spambots. You need JavaScript enabled to view it.